Introduction to Animal Models of Skin Itch

Skin‑itch animal models primarily employ topical application or subcutaneous injection of specific pruritogens to chronically mimic the persistent epidermal barrier disruption, immune cell infiltration, and peripheral nerve sensitization observed in human chronic dermatitis, eczema, or systemic diseases. In clinical studies, the severity of itch in these models and the targeted efficacy of anti‑pruritic agents are typically assessed by quantitatively monitoring, via electronic recording or manual observation, the frequency and duration of scratching behavior—specifically, the hind limbs rubbing against the trunk.

Service Advantages of the Aniphe BioLab Skin Itch Animal Model Platform

Aniphe BioLab offers a standardized, end-to-end service platform for animal models of skin pruritus, featuring multiple well-established modeling protocols paired with a comprehensive evaluation system. We provide one-stop support for assessing the efficacy of pharmaceuticals and skincare products, ensuring data compliance and seamless integration into scientific publications and regulatory submissions.

	Feeding System Standards We have our own SPF animal facility, with standardized management and control, resulting in minimal individual variability and high experimental reproducibility.
	The evaluation dimensions are comprehensive. Quantitative behavioral analysis of itch, combined with multi-level pharmacological efficacy assessments of the skin barrier, pathology, and inflammatory cytokines.
	Extensive experience in model creation. Mature and optimized modeling protocols, ample stock animals, and a shortened overall experimental timeline.
	One-stop all-inclusive service End-to-end outsourcing covering the entire workflow, from animal husbandry and model establishment to drug administration, sample analysis, and report generation.
	Supports customized models It is possible to generate itch‑related gene‑edited animal models, facilitating in-depth mechanistic studies of target pathways.

Modeling cycle	1 day
Laboratory animals	Adult C57BL/6 or BALB/c mice
Positive drug	Histamine-dependent pruritus is assessed using antihistamines (such as loratadine and cetirizine) as positive controls; non-histamine-dependent pruritus is evaluated using κ‑opioid agonists (such as nalfurafine) or Mrgpr antagonists as controls.
Application areas	Distinguish between histaminergic and non-histaminergic itch pathways, screen for acute antipruritic compounds, and investigate the functions of pruritus‑sensing neurons (such as MrgprA3⁺ neurons).

Establishment of an Animal Model of Cutaneous Pruritus

01 Chloroquine (CQ) subcutaneous injection–induced pruritus model

Chloroquine solution is administered by subcutaneous injection into the skin of the nape of the neck in mice at a predetermined dose. Chloroquine can activate itch‑related receptors such as MrgprA3, thereby eliciting a non‑histamine‑dependent pruritic response. Following administration, animals typically exhibit marked scratching behavior within a short time, characterized by an increased frequency and duration of scratching. This model is primarily used to investigate the mechanisms underlying non‑histamine‑mediated chronic pruritus and to evaluate the efficacy of anti‑pruritic agents targeting neuroimmune regulatory pathways.

02 Histamine Intradermal Injection–Induced Pruritus Model

Histamine solution is quantitatively injected into the dermis of the mouse’s back or nape. By activating histamine H1 and H4 receptors, this induces a typical histamine‑dependent pruritic response. Following injection, animals promptly exhibit frequent scratching, accompanied by local erythema, edema, and other inflammatory signs. This model is easy to perform, highly reproducible, and widely used for investigating the mechanisms underlying histamine‑related pruritus and for evaluating the efficacy of antihistamine drugs.

Model characteristics: The chloroquine‑induced model primarily mimics non‑histamine‑dependent pruritus, whereas the histamine‑induced model predominantly reflects histamine‑mediated itch pathways. Combining these two models enables a systematic evaluation of candidate drugs’ effects on distinct itch mechanisms, providing crucial experimental evidence for research on chronic cutaneous pruritus–related disorders and for the development of new therapeutics.